vTv Therapeutics Inc. financial data

Symbol
VTVT on Nasdaq
Industry
Pharmaceutical Preparations
Location
3980 Premier Dr, Suite 310, High Point, NC
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 328 % +19.8%
Debt-to-equity -896 % -471%
Return On Equity 638 % +499%
Return On Assets -63.8 % -0.03%
Operating Margin -2.29K % +99.3%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 22.9M USD +0.69%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1M USD +11011%
Research and Development Expense 11.1M USD -29.4%
General and Administrative Expense 12.8M USD +8.39%
Operating Income (Loss) -22.9M USD +16.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25.3M USD -3.12%
Income Tax Expense (Benefit) 100K USD
Net Income (Loss) Attributable to Parent -20.2M USD -5.51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.5M USD +261%
Accounts Receivable, after Allowance for Credit Loss, Current 306K USD
Assets, Current 46.2M USD +231%
Property, Plant and Equipment, Net 72K USD -55.6%
Operating Lease, Right-of-Use Asset 186K USD -37.8%
Assets 46.5M USD +107%
Accounts Payable, Current 4.08M USD +65.6%
Contract with Customer, Liability, Current 17K USD 0%
Liabilities, Current 6.99M USD -24.8%
Contract with Customer, Liability, Noncurrent 18.7M USD 0%
Operating Lease, Liability, Noncurrent 79K USD -69.1%
Liabilities 26M USD -9.74%
Retained Earnings (Accumulated Deficit) -291M USD -3.74%
Stockholders' Equity Attributable to Parent 16.5M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 20.4M USD
Liabilities and Equity 46.5M USD +107%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.34M USD -42%
Net Cash Provided by (Used in) Financing Activities 50.1M USD +325%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 42.8M USD +545%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.5M USD +261%
Deferred Tax Assets, Valuation Allowance 29M USD +18.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 29M USD +18.8%
Operating Lease, Liability 256K USD -38.6%
Depreciation 22K USD 0%
Lessee, Operating Lease, Liability, to be Paid 274K USD -41.5%
Property, Plant and Equipment, Gross 604K USD 0%
Operating Lease, Liability, Current 177K USD +9.94%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 177K USD -8.76%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 23.7M USD +16.8%
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.92M USD +39.7%
Interest Expense 13K USD -13.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares